Aktis Oncology Closes Upsized IPO Raising $365.4 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2026
0mins
Should l Buy AKTS?
Source: Globenewswire
- Successful IPO: Aktis Oncology completed its initial public offering of 17.65 million shares on January 12, 2026, at an IPO price of $18 per share, indicating strong market demand for its targeted radiopharmaceuticals.
- Additional Share Purchase: Underwriters fully exercised their option to purchase an additional 2.6475 million shares, expected to close on January 14, 2026, further strengthening the company's financial position to support R&D and market expansion.
- Significant Fundraising: The total gross proceeds from the offering are expected to reach approximately $365.4 million, reflecting investor confidence in Aktis's innovative potential in cancer treatment and providing ample funding for future product development.
- Strong Market Debut: Aktis's stock began trading on the Nasdaq Global Select Market on January 9, 2026, under the ticker symbol “AKTS,” marking a successful entry into the capital markets and likely enhancing its brand visibility and competitive position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AKTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AKTS
Wall Street analysts forecast AKTS stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 15.190
Low
30.00
Averages
31.67
High
34.00
Current: 15.190
Low
30.00
Averages
31.67
High
34.00
About AKTS
Aktis Oncology, Inc. is a clinical-stage oncology company. The Company is focused on expanding the potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The Company’s proprietary mini-protein radio conjugate platform aims to safely confer efficacy to a range of patient populations. Its mini-protein radio conjugates are designed to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors with high tumor penetration and prolonged retention, while being rapidly cleared from normal organs and tissues to minimize systemic radiation exposure. Its pipeline includes AKY-1189 and AKY-2519. AKY-1189, is targeting Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, colorectal cancer and cervical cancer. AKY-2519 targets B7-H3 expressing solid tumors, such as prostate, lung and breast cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aktis Oncology Advances Targeted Radiopharmaceutical Development
- Clinical Trial Progress: Aktis Oncology announced FDA clearance of IND applications for AKY-2519, with plans to initiate a Phase 1b clinical trial in mid-2026, aimed at providing new treatment options for patients with various solid tumors such as prostate and lung cancer, thereby expanding the reach of targeted radiopharmaceuticals.
- Improved Financial Position: The company raised $365.4 million in gross proceeds from its IPO in 2025, significantly enhancing its cash flow and positioning it to fund operations into 2029, demonstrating strong performance in the capital markets.
- Increased R&D Investment: Research and development expenses reached $67.5 million in 2025, up from $41.0 million in 2024, primarily to support clinical studies for AKY-1189 and AKY-2519, indicating the company's commitment to advancing new drug development.
- Collaboration Revenue Growth: Collaboration revenue increased to $6.5 million in 2025 from $1.5 million in 2024, reflecting successful outcomes from the partnership with Eli Lilly, which enhances the company's market competitiveness and business expansion capabilities.
See More
Aktis Oncology Reports FY 2025 Financial Results
- Increased Net Loss: Aktis Oncology reported a net loss of $63.7 million for FY 2025, up from $44.0 million in 2024, primarily driven by rising R&D expenses, indicating ongoing investment and associated risks in drug development.
- Revenue Growth Challenges: Despite a 333.3% year-over-year revenue increase to $6.5 million, the figure fell short of expectations by $0.41 million, highlighting challenges in market acceptance and sales strategies.
- Cash Flow Status: As of December 31, 2025, the company held $226.8 million in cash and marketable securities, down from $297.2 million in 2024, reflecting pressures on financial management amid rising operational costs.
- Successful IPO Financing: Aktis Oncology completed its IPO in January 2026, generating approximately $335.3 million in net proceeds, resulting in a pro forma cash position of $562.1 million, which is expected to fund operations through 2029, thereby enhancing financial stability for future growth.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting the latest market perspectives and expectations for these companies.
- Market Dynamics: While specific stock names are not disclosed, changes in analyst ratings typically influence investor decisions, potentially leading to price volatility in the affected stocks.
- Investor Focus: For those considering buying AKTS stock, analysts' opinions will serve as a crucial reference point, aiding in the assessment of investment risks and potential returns.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, even though specific rating details are not available.
See More
FDA Grants Fast Track Designation to AKY-1189 for Urothelial Cancer Treatment
- FDA Fast Track Designation: The U.S. FDA has granted Fast Track designation to AKY-1189 for the treatment of locally advanced or metastatic urothelial cancer, aimed at expediting the development and review process to address this unmet medical need.
- Clinical Trial Progress: Aktis is conducting a multi-site Phase 1b clinical trial involving various tumor types, including locally advanced or metastatic urothelial cancer, with preliminary results expected in Q1 2027, further validating the efficacy of AKY-1189.
- Targeted Treatment Potential: AKY-1189 utilizes Aktis' miniprotein radioconjugate platform to specifically target Nectin-4 expressing tumors, with approximately 80-90% of urothelial cancer patients showing positive Nectin-4 expression, indicating broad applicability.
- Strategic Collaboration Opportunities: Aktis has established a strategic collaboration with Eli Lilly to leverage its miniprotein platform for developing novel radioconjugates, further expanding the indications for AKY-1189 and enhancing the company's market competitiveness in oncology.
See More
2026 IPO Market Starts Steadily with $2.6 Billion Raised
- IPO Market Performance: In January 2026, nine IPOs raised a total of $2.6 billion, although a backlog of startups indicated IPO plans, the overall deal count and proceeds fell below the ten-year average, reflecting cautious market sentiment.
- Sector Dynamics: The industrial sector's EquipmentShare.com led with $747 million raised, surging 33% on its first day, indicating strong investor demand for fast-growing companies viewed as resistant to AI disruption.
- SPAC Issuance Surge: January saw SPAC issuance reach a four-year high with 25 blank check deals raising $5.2 billion, providing hundreds of pre-IPO companies with an alternative path to public markets, reflecting growing interest in emerging technology firms.
- Active IPO Pipeline: By the end of January, the IPO pipeline included 216 companies seeking to raise approximately $12.4 billion, with 130 having filed or updated within the last 90 days, demonstrating ongoing market interest in new public offerings.
See More
2026 IPO Market Starts Steadily with $2.6 Billion Raised
- IPO Market Performance: In January 2026, nine IPOs raised a total of $2.6 billion, reflecting a cautious market sentiment as this figure fell short of the ten-year average, particularly after the volatility experienced in Q4 2025.
- Sector Dynamics: The industrial sector led the month’s largest IPOs, with EquipmentShare.com raising $747 million, highlighting investor preference for fast-growing companies perceived as resilient to AI disruption.
- Emerging Trends: The fintech and biotech sectors showed signs of recovery at the start of 2026, notably with fintech PicPay becoming the first Brazilian IPO in four years, raising $434 million, although its shares fell 5% post-IPO.
- SPAC Activity: January saw SPAC issuance reach a four-year high with 25 deals raising $5.2 billion, indicating growing interest in pre-IPO companies opting for SPAC mergers, despite overall IPO activity remaining below 2021 peaks.
See More
Aktis Oncology Advances Targeted Radiopharmaceutical Development
- Clinical Trial Progress: Aktis Oncology announced FDA clearance of IND applications for AKY-2519, with plans to initiate a Phase 1b clinical trial in mid-2026, aimed at providing new treatment options for patients with various solid tumors such as prostate and lung cancer, thereby expanding the reach of targeted radiopharmaceuticals.
- Improved Financial Position: The company raised $365.4 million in gross proceeds from its IPO in 2025, significantly enhancing its cash flow and positioning it to fund operations into 2029, demonstrating strong performance in the capital markets.
- Increased R&D Investment: Research and development expenses reached $67.5 million in 2025, up from $41.0 million in 2024, primarily to support clinical studies for AKY-1189 and AKY-2519, indicating the company's commitment to advancing new drug development.
- Collaboration Revenue Growth: Collaboration revenue increased to $6.5 million in 2025 from $1.5 million in 2024, reflecting successful outcomes from the partnership with Eli Lilly, which enhances the company's market competitiveness and business expansion capabilities.
See More
Aktis Oncology Reports FY 2025 Financial Results
- Increased Net Loss: Aktis Oncology reported a net loss of $63.7 million for FY 2025, up from $44.0 million in 2024, primarily driven by rising R&D expenses, indicating ongoing investment and associated risks in drug development.
- Revenue Growth Challenges: Despite a 333.3% year-over-year revenue increase to $6.5 million, the figure fell short of expectations by $0.41 million, highlighting challenges in market acceptance and sales strategies.
- Cash Flow Status: As of December 31, 2025, the company held $226.8 million in cash and marketable securities, down from $297.2 million in 2024, reflecting pressures on financial management amid rising operational costs.
- Successful IPO Financing: Aktis Oncology completed its IPO in January 2026, generating approximately $335.3 million in net proceeds, resulting in a pro forma cash position of $562.1 million, which is expected to fund operations through 2029, thereby enhancing financial stability for future growth.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting the latest market perspectives and expectations for these companies.
- Market Dynamics: While specific stock names are not disclosed, changes in analyst ratings typically influence investor decisions, potentially leading to price volatility in the affected stocks.
- Investor Focus: For those considering buying AKTS stock, analysts' opinions will serve as a crucial reference point, aiding in the assessment of investment risks and potential returns.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, even though specific rating details are not available.
See More
FDA Grants Fast Track Designation to AKY-1189 for Urothelial Cancer Treatment
- FDA Fast Track Designation: The U.S. FDA has granted Fast Track designation to AKY-1189 for the treatment of locally advanced or metastatic urothelial cancer, aimed at expediting the development and review process to address this unmet medical need.
- Clinical Trial Progress: Aktis is conducting a multi-site Phase 1b clinical trial involving various tumor types, including locally advanced or metastatic urothelial cancer, with preliminary results expected in Q1 2027, further validating the efficacy of AKY-1189.
- Targeted Treatment Potential: AKY-1189 utilizes Aktis' miniprotein radioconjugate platform to specifically target Nectin-4 expressing tumors, with approximately 80-90% of urothelial cancer patients showing positive Nectin-4 expression, indicating broad applicability.
- Strategic Collaboration Opportunities: Aktis has established a strategic collaboration with Eli Lilly to leverage its miniprotein platform for developing novel radioconjugates, further expanding the indications for AKY-1189 and enhancing the company's market competitiveness in oncology.
See More
2026 IPO Market Starts Steadily with $2.6 Billion Raised
- IPO Market Performance: In January 2026, nine IPOs raised a total of $2.6 billion, although a backlog of startups indicated IPO plans, the overall deal count and proceeds fell below the ten-year average, reflecting cautious market sentiment.
- Sector Dynamics: The industrial sector's EquipmentShare.com led with $747 million raised, surging 33% on its first day, indicating strong investor demand for fast-growing companies viewed as resistant to AI disruption.
- SPAC Issuance Surge: January saw SPAC issuance reach a four-year high with 25 blank check deals raising $5.2 billion, providing hundreds of pre-IPO companies with an alternative path to public markets, reflecting growing interest in emerging technology firms.
- Active IPO Pipeline: By the end of January, the IPO pipeline included 216 companies seeking to raise approximately $12.4 billion, with 130 having filed or updated within the last 90 days, demonstrating ongoing market interest in new public offerings.
See More
2026 IPO Market Starts Steadily with $2.6 Billion Raised
- IPO Market Performance: In January 2026, nine IPOs raised a total of $2.6 billion, reflecting a cautious market sentiment as this figure fell short of the ten-year average, particularly after the volatility experienced in Q4 2025.
- Sector Dynamics: The industrial sector led the month’s largest IPOs, with EquipmentShare.com raising $747 million, highlighting investor preference for fast-growing companies perceived as resilient to AI disruption.
- Emerging Trends: The fintech and biotech sectors showed signs of recovery at the start of 2026, notably with fintech PicPay becoming the first Brazilian IPO in four years, raising $434 million, although its shares fell 5% post-IPO.
- SPAC Activity: January saw SPAC issuance reach a four-year high with 25 deals raising $5.2 billion, indicating growing interest in pre-IPO companies opting for SPAC mergers, despite overall IPO activity remaining below 2021 peaks.
See More
